Adaptive Biotechnologies Corporation

NASDAQ:ADPT

Biotechnology

Healthcare
$28.46 +3.66%

+$0.61 today

Market cap
$4.61B
Beta
2.15
P/E (TTM)
-54.5
EPS (TTM)
-$0.32
52W Low $9.96High $20.76

Volume 2.21M

Average 1.94M

ADPT Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Adaptive Biotechnologies CorporationNASDAQ: ADPT

Net Margin · Q2 FY2026 · quarter ended Jun 2026

Net margin narrows to -55.6%

Net margin was -55.6% in Q2 FY2026, down 12.1 pp from a year earlier. On a trailing-twelve-month basis it was -20.7%, up 38.3 pp year over year. Over 3 fiscal years it widened by 86.5 pp.

Context

  • Net margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 6 analysts of -19.9% for the fiscal year ending Dec 2026, up from -21.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-55.6%-27.3 pp QoQ
Last fiscal yearDec 2025
-21.5%+67.6 pp YoY
LTMJun 2026
-20.7%+38.3 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-12.1 pp-33.9 pp-21.8 pp
1 year+67.6 pp+1.6 pp-66.1 pp
3 years+86.5 pp+26.2 pp-60.3 pp
5 years+22.4 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-21.5%
Year-over-year change
+67.6pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How ADPT compares with its peers on the latest reported figures

  • ADPT's LTM Jun 2026 net margin of -20.7% is the 3rd highest of the 8 companies compared; the peer median is -54.7%.
  • Its year-over-year change of +38.3 pp is the 3rd highest of 7, against a peer median of +17.1 pp.
  • Over three fiscal years its change of +86.5 pp compares with a peer median of +196.9 pp.
ADPT Competitors Peer median
Net Margin for ADPT and competitors
Company Period LTM level YoY 3-year change
CPRXCatalyst Pharmaceuticals, Inc.LTM Mar 202637.1% +0.2 pp-2.4 pp
LEGNLegend Biotech CorporationLTM Sep 2026-0.0% +26.4 pp+352.6 pp
ADPTAdaptive Biotechnologies CorporationLTM Jun 2026-20.7% +38.3 pp+86.5 pp
ZLABZai Lab LimitedLTM Jun 2026-41.9% +7.8 pp+168.0 pp
BEAMBeam Therapeutics Inc.LTM Jun 2026-54.7% +606.6 pp+417.3 pp
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026-62.2% +4313.7 pp+63.2 pp
TARSTarsus Pharmaceuticals, Inc.LTM Sep 2026-102.9% -80.8 pp+225.8 pp
SRRKScholar Rock Holding CorporationLTM Sep 2026-72563.2% ——
IRONDisc Medicine, Inc.FY2025— ——
MLYSMineralys Therapeutics, Inc.FY2025— ——
Peer median (excluding ADPT) -54.7%+17.1 pp+196.9 pp

Competitors are the stored peer set for ADPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue154.34M185.31M170.28M178.96M276.98M
Cost of Revenue49.3M57.91M75.55M72.08M71.36M
Gross Profit105.04M127.4M94.72M106.88M205.62M
Gross Margin68.1%68.7%55.6%59.7%74.2%
Research & Development142.34M141.76M122.12M102.95M93.77M
Selling, General & Admin169.97M184.13M172.51M157.57M167.27M
Operating Expenses314.01M327.59M321.76M269.43M262.74M
Depreciation & Amortization13.95M20.92M22.23M19.26M17.83M
EBITDA(193.35M)(175.21M)(189.27M)(128.76M)(29.85M)
EBITDA Margin-125.3%-94.6%-111.2%-71.9%-10.8%
Operating Income(208.97M)(200.19M)(227.04M)(162.55M)(57.12M)
Operating Margin-135.4%-108.0%-133.3%-90.8%-20.6%
Interest Income1.67M4.06M15.53M14.53M9.44M
Interest Expense04.24M13.8M11.58M11.78M
Other Income / Expenses1.67M(182K)1.73M2.95M(2.33M)
Income Before Tax(207.3M)(200.37M)(225.3M)(159.6M)(59.46M)
Pre-Tax Margin-134.3%-108.1%-132.3%-89.2%-21.5%
Income Tax Expense00000
Net Income(207.28M)(200.19M)(225.25M)(159.49M)(59.5M)
Net Margin-134.3%-108.0%-132.3%-89.1%-21.5%
EPS (Basic)(1.46)(1.00)(1.56)(1.08)(0.39)
EPS (Diluted)(1.46)(1.00)(1.56)(1.08)(0.39)
Weighted Avg Shares140.35M142.52M144.38M147.1M151.72M
Weighted Avg Shares (Diluted)140.35M142.52M144.38M147.1M151.72M

Adaptive Biotechnologies Corporation

NASDAQ:ADPT

Intrinsic Alpha fair value

Locked

Current Price

$28.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.